Results published at the annual San Antonio Breast Cancer Symposium, said that Abraxane in combination with Xeloda may be an effective treatment option for patients with metastatic breast cancer.Abraxane is a newer form of Taxol that uses albumin, a natural protein found in the body, to deliver high concentrations of the active ingredient into the cancer cells and has fewer side effect than Taxol. Abraxane treatments last around 30 minutes compared with 3 hours for Taxol.

Researchers conducted a small clinical trial that included 38 patients with metastatic breast cancer. Complete disappearance of cancer was achieved in nearly 9 percent of patients. Partial responses were achieved in about 44 percent of patients. Disease stabilization was seen in almost 33 percent of study participants.

Even though the study was a small one, researchers conclude that it appears that treatment with Abraxane and Xeloda may be effective for patients with metastatic breast cancer.